

## Redbiotec sells CMV program to Pfizer

Schlieren, Zurich, Switzerland. 7.1.2015

Privately held Swiss Biopharmaceutical Company Redbiotec based in Zurich-Schlieren recently announced that it has sold Redvax GmbH, a spin-off from Redbiotec AG, to Pfizer. This transaction provides Pfizer with access to a preclinical human cytomegalovirus (CMV) vaccine candidate, as well as intellectual property and a technology platform related to a second, undisclosed vaccine program (see Pfizer press release [http://www.pfizer.com/news/press-release/press-release-detail/pfizer\\_acquires\\_redvax\\_gmbh](http://www.pfizer.com/news/press-release/press-release-detail/pfizer_acquires_redvax_gmbh)). Redbiotec will keep its core technology for all further applications.

Christian Schaub, CEO of Redbiotec and Managing Director of Redvax commented, “We are pleased to have completed this deal with Pfizer, a global leader in vaccines. This represents an important step toward the development of a much needed vaccine for CMV, a disease that has a devastating impact on children and families. We believe that combining Redvax’s assets with Pfizer’s commitment, expertise, and resources will significantly enhance the potential of developing this vaccine for patients”.

Erika Puyal, Head of Start-up finance, Zürcher Kantonalbank commented, “We are pleased that with this transaction research and development of the vaccine will continue in the Zurich area. This has been a successful investment for ZKB as an early stage start up investor.”

Dr. Jürg F. Geigy, another investor of Redbiotec, commented on the deal with Pfizer: “This acquisition by Pfizer of Redvax, a Redbiotec spin out company containing CMV vaccine assets, is an innovative approach to deal making in the biotech industry. Hopefully this may trigger similar transactions for other young biotech companies”.